Labs / Assays & in vitro testing
Harbour BioMed
Shanghai, China · harbourbiomed.com
On your own
Free. Their own form.
Through Midgard
Midgard sends your request to the lab and keeps the order's messages, papers and payments in one place. Free to ask. 1% platform fee if you keep the order on Midgard.
Harbour BioMed is a biopharmaceutical company focused on discovering and developing novel antibody therapeutics. It serves global partners from R&D centers in China, the United States, and Europe, with work spanning antibody discovery platforms, clinical development, and strategic collaborations.
They take quote requests by email.
What they offer
Harbour Mice® antibody technology platform
Generates fully human monoclonal antibodies in H2L2 and heavy chain-only (HCAb) formats.
Single Cell Technology Platform
Provides a full single B cell cloning process including enrichment, separation, screening, sequencing, recombinant antibody production, and verification.
HBICE® bispecific antibody technology
Uses HCAb-based immune cell engagers to generate flexible bispecific formats for different mechanisms of action.
HCAb PLUS™ technology
Provides modality solutions for developing innovative multi-specific medicines across disease areas.
Generative AI HCAb Model
Uses the Hu-mAtrIx™ AI platform to support fully human HCAb model development and accelerate therapy generation.
Clinical Development & Medical Services
Delivers integrated clinical development from first-in-human studies through pivotal registration studies and post-marketing studies.
Co-development
Shares design, execution, and risk of clinical trials with global partners.
Technology Service
Provides technology support through fee-for-service and FTE arrangements.
Technology License
Offers access to the Harbour Mice® platform for external partners.
Asset License
Licenses novel pipelines with potential for global innovation.
Strategic Collaboration
Supports long-term collaboration to develop next-generation therapeutics.
What they work on
- Modalities
- Small molecule, Antibody, Bispecific, ADC
- Species and models
- murine CD138+ plasma cell, single B cell, mammalian display libraries, yeast display libraries, phage display libraries
- Assays and studies
- single B cell cloning, single B cell separation, antibody binding screening, functional in-chip screening, single-cell antibody sequencing, high-throughput recombinant antibody production, antibody verification
- Instruments and platforms
- optofluidic technology, next-generation sequencing
- Scale and capacity
- 150+ partners, 400+ projects, 20+ IND/clinical stage, 140+ partners, 380+ projects, over 100 senior scientists
- Therapeutic areas
- immunology, oncology, immuno-oncology, weight management
- Sites
- Shanghai, China · Shanghai, China · Beijing, China · Beijing, China · Suzhou, China · Hong Kong, China · Natick, MA, United States of America · Rotterdam, Netherlands
- Team
- over 100 scientists
- Serves
- global, China, United States, Europe
- Founded
- 2016
Public records
- Ownership
- Harbour BioMed Therapeutics Limited · KY GLEIF
Similar labs. Invenra, Sparx BIO, Aurigene Pharmaceutical Services, Kyinno Bio
Found in a contract services directory. Listing built from harbourbiomed.com. Work here? Claim this listing.